MX385229B - Composiciones farmaceuticas que comprenden un antagonista de integrina alfa4 para uso en el tratamiento de condiciones inflamatorias oculares. - Google Patents

Composiciones farmaceuticas que comprenden un antagonista de integrina alfa4 para uso en el tratamiento de condiciones inflamatorias oculares.

Info

Publication number
MX385229B
MX385229B MX2017017163A MX2017017163A MX385229B MX 385229 B MX385229 B MX 385229B MX 2017017163 A MX2017017163 A MX 2017017163A MX 2017017163 A MX2017017163 A MX 2017017163A MX 385229 B MX385229 B MX 385229B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
treatment
integrin antagonist
ocular conditions
alpha4 integrin
Prior art date
Application number
MX2017017163A
Other languages
English (en)
Other versions
MX2017017163A (es
Inventor
Achim Hans- Peter Krauss
Original Assignee
Axerovision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axerovision Inc filed Critical Axerovision Inc
Publication of MX2017017163A publication Critical patent/MX2017017163A/es
Publication of MX385229B publication Critical patent/MX385229B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se relaciona a antagonistas de integrina a4 y su uso en composiciones farmacéuticas, composiciones oftálmicas principalmente administradas tópicamente. Las composiciones farmacéuticas son útiles para tratar condiciones inflamatorias oculares, tales como enfermedad de ojo seco, uveítis no infecciosa (por ejemplo, anterior, intermedia, posterior, uveítis longitudinal), conjuntivitis no infecciosa, iritis o escleritis en animales, y particularmente mamíferos, incluyendo humanos.
MX2017017163A 2015-07-08 2016-07-07 Composiciones farmaceuticas que comprenden un antagonista de integrina alfa4 para uso en el tratamiento de condiciones inflamatorias oculares. MX385229B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08
PCT/IB2016/054073 WO2017006272A1 (en) 2015-07-08 2016-07-07 Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions

Publications (2)

Publication Number Publication Date
MX2017017163A MX2017017163A (es) 2018-08-09
MX385229B true MX385229B (es) 2025-03-14

Family

ID=56373100

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017017163A MX385229B (es) 2015-07-08 2016-07-07 Composiciones farmaceuticas que comprenden un antagonista de integrina alfa4 para uso en el tratamiento de condiciones inflamatorias oculares.

Country Status (21)

Country Link
US (3) US10413535B2 (es)
EP (1) EP3319639B1 (es)
JP (2) JP6752276B2 (es)
KR (2) KR20220062688A (es)
CN (1) CN107921136A (es)
AU (1) AU2016290197B2 (es)
BR (1) BR112018000112A2 (es)
CA (1) CA2989522C (es)
CL (1) CL2018000057A1 (es)
ES (1) ES2835274T3 (es)
HK (1) HK1247120A1 (es)
IL (2) IL256770B (es)
MA (2) MA42016A1 (es)
MX (1) MX385229B (es)
MY (1) MY187552A (es)
PL (1) PL3319639T3 (es)
RU (1) RU2018103940A (es)
TN (1) TN2017000538A1 (es)
UA (1) UA123728C2 (es)
WO (1) WO2017006272A1 (es)
ZA (1) ZA201708601B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200004789A (ko) * 2017-03-09 2020-01-14 알리스타 파마슈티컬즈, 인크. 안구 건조증 질환을 위한 펩티드
US10555947B2 (en) * 2017-05-19 2020-02-11 Ocugen, Inc. Ophthalmic compositions and methods of use
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
EP4003392A4 (en) * 2019-07-26 2023-08-09 Allegro Pharmaceuticals, LLC PEPTIDES FOR THE TREATMENT OF NON-EXCESSIVE MACULAR DEGENERATION AND OTHER EYE DISEASES
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
US20240158375A1 (en) * 2020-10-21 2024-05-16 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
US8168655B2 (en) * 2005-05-17 2012-05-01 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
ZA200804550B (en) * 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
US20200000786A1 (en) 2020-01-02
US10413535B2 (en) 2019-09-17
MA42016A1 (fr) 2018-03-30
UA123728C2 (uk) 2021-05-26
KR102440162B1 (ko) 2022-09-02
TN2017000538A1 (en) 2019-04-12
US10751334B2 (en) 2020-08-25
IL256770B (en) 2021-02-28
KR20220062688A (ko) 2022-05-17
JP2018521126A (ja) 2018-08-02
CA2989522C (en) 2022-10-18
CL2018000057A1 (es) 2018-06-22
MA44935A1 (fr) 2019-08-30
US20180200240A1 (en) 2018-07-19
PL3319639T3 (pl) 2021-03-08
WO2017006272A1 (en) 2017-01-12
CN107921136A (zh) 2018-04-17
HK1247120A1 (zh) 2018-09-21
KR20180041122A (ko) 2018-04-23
ZA201708601B (en) 2019-05-29
AU2016290197B2 (en) 2021-07-22
JP2020121985A (ja) 2020-08-13
CA2989522A1 (en) 2017-01-12
IL280827A (en) 2021-04-29
MX2017017163A (es) 2018-08-09
IL256770A (en) 2018-03-29
EP3319639B1 (en) 2020-11-18
RU2018103940A (ru) 2019-08-08
JP6752276B2 (ja) 2020-09-09
US20200405703A1 (en) 2020-12-31
AU2016290197A1 (en) 2018-01-04
ES2835274T3 (es) 2021-06-22
EP3319639A1 (en) 2018-05-16
MY187552A (en) 2021-09-29
BR112018000112A2 (pt) 2018-09-04
RU2018103940A3 (es) 2019-09-03

Similar Documents

Publication Publication Date Title
MX2017017163A (es) Composiciones farmaceuticas que comprenden un antagonista de integrina alfa4 para uso en el tratamiento de condiciones inflamatorias oculares.
UY39630A (es) Inhibidores de bromodominios
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2020005459A2 (es) Compuestos bicíclicos en puente como moduladores del receptor farnesoide x
CO2018004800A2 (es) Antagonistas del receptor muscarinico 4 y metodos de uso.
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
DOP2015000305A (es) Inhibidores de bromodominios
CL2018002924A1 (es) Inhibidores de bromodominios
CO2017012991A2 (es) Agonistas de triazol del receptor apj
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CL2018003060A1 (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
SV2016005206A (es) Derivados novedosos de amino pirimidina
MX2020012520A (es) Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia.
SV2016005316A (es) Compuestos y composiciones para inducir condrogénesis
CO2017011017A2 (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
UY35972A (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
MX2017007284A (es) Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas.